In vitro activity of 4'-iodo-4'-deoxydoxorubicin on human colo-rectal cancer as measured by a short-term antimetabolic assay
- PMID: 2384300
- DOI: 10.1007/BF00177248
In vitro activity of 4'-iodo-4'-deoxydoxorubicin on human colo-rectal cancer as measured by a short-term antimetabolic assay
Abstract
A short-term antimetabolic assay based upon the inhibition of incorporation of nucleic acid precursors was used to compare the cytotoxicity of a new halogenated anthracycline, 4'-iodo-4'-deoxydoxorubicin (IDX), with that of its parent compound doxorubicin (DX) on human colo-rectal carcinoma specimens. IDX showed a marked dose-dependent effect, with frequencies of activity consistently greater than those of DX at all concentrations. The minimal dose required to induce a significant antimetabolic effect for IDX was 1/10 that for DX.
Similar articles
-
Absolute and relative activities of 4' -iodo-4'-deoxydoxorubicin against human colo-rectal tumors, as evaluated by a short-term in vitro assay.Anticancer Res. 1990 Jan-Feb;10(1):105-8. Anticancer Res. 1990. PMID: 2334114
-
Fractional incorporation of radionucleotides, a marker of in vitro tumor cell chemosensitivity in colorectal cancer.Oncology. 1991;48(6):510-6. doi: 10.1159/000226991. Oncology. 1991. PMID: 1749592
-
Anthracycline in colorectal carcinoma: an in vitro short-term assay to predict drug sensitivity. Preliminary results.Tumori. 1987 Feb 28;73(1):69-73. doi: 10.1177/030089168707300114. Tumori. 1987. PMID: 3469807
-
Comparative in vitro activity of 4'-deoxy-4'-iododoxorubicin and other anthracyclines in the human tumor clonogenic assay.Invest New Drugs. 1987;5(3):231-4. doi: 10.1007/BF00175292. Invest New Drugs. 1987. PMID: 3478322
-
[Iodo-doxorubicin, a new anthracycline derivative. Current state of progress].Onkologie. 1990 Oct;13(5):346-51. doi: 10.1159/000216794. Onkologie. 1990. PMID: 2082229 Review. German.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical